Endometrin Patent Expiration

Endometrin is a drug owned by Ferring Pharmaceuticals Inc. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 17, 2019. Details of Endometrin's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7320800 Vaginally administrable progesterone-containing tablets and method for preparing same
Nov, 2019

(4 years ago)

Expired
US7393543 Vaginally administratable progesterone-containing tablets and method for preparing same
Nov, 2019

(4 years ago)

Expired
US7300664 Vaginally administrable progesterone-containing tablets and method for preparing same
Nov, 2019

(4 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Endometrin's patents.

Given below is the list of recent legal activities going on the following patents of Endometrin.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 24 Dec, 2019 US7393543
Payment of Maintenance Fee, 12th Year, Large Entity 15 Jul, 2019 US7320800
Payment of Maintenance Fee, 12th Year, Large Entity 20 May, 2019 US7300664
Post Issue Communication - Certificate of Correction 28 Oct, 2009 US7393543
Correspondence Address Change 24 Aug, 2009 US7393543
Correspondence Address Change 24 Aug, 2009 US7320800
Correspondence Address Change 24 Aug, 2009 US7300664
Recordation of Patent Grant Mailed 01 Jul, 2008 US7393543
Patent Issue Date Used in PTA Calculation 01 Jul, 2008 US7393543
Issue Notification Mailed 11 Jun, 2008 US7393543

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Endometrin is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Endometrin's family patents as well as insights into ongoing legal events on those patents.

Endometrin's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Endometrin's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 17, 2019 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Endometrin Generics:

Progesterone is the generic name for the brand Endometrin. 11 different companies have already filed for the generic of Endometrin, with Xiromed having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Endometrin's generic

Alternative Brands for Endometrin

Endometrin which is used for supporting embryo implantation and early pregnancy in infertile women undergoing assisted reproductive technology (ART) treatment., has several other brand drugs using the same active ingredient (Progesterone). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Allergan
Crinone
Covis
Makena (autoinjector)
Ferring Pharms Inc
Milprosa
Mayne Pharma
Bijuva
Pfizer
Depo-subq Provera 104
Wyeth Pharms
Premphase 14/14
Prempro


Apart from brand drugs containing the same ingredient, some generics have also been filed for Progesterone, Endometrin's active ingredient. Check the complete list of approved generic manufacturers for Endometrin





About Endometrin

Endometrin is a drug owned by Ferring Pharmaceuticals Inc. It is used for supporting embryo implantation and early pregnancy in infertile women undergoing assisted reproductive technology (ART) treatment. Endometrin uses Progesterone as an active ingredient. Endometrin was launched by Ferring in 2007.

Approval Date:

Endometrin was approved by FDA for market use on 21 June, 2007.

Active Ingredient:

Endometrin uses Progesterone as the active ingredient. Check out other Drugs and Companies using Progesterone ingredient

Treatment:

Endometrin is used for supporting embryo implantation and early pregnancy in infertile women undergoing assisted reproductive technology (ART) treatment.

Dosage:

Endometrin is available in insert form for vaginal use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
100MG INSERT Prescription VAGINAL